Bristol-Myers Squibb (BMY) Scheduled to Post Earnings on Friday
Bristol-Myers Squibb (NYSE:BMY) is scheduled to be posting its quarterly earnings results on Friday, January 24th. Parties that wish to register for the company’s conference call can do so using this link.
Bristol-Myers Squibb (NYSE:BMY) opened at 54.81 on Thursday. Bristol-Myers Squibb has a 52-week low of $34.90 and a 52-week high of $56.83. The stock’s 50-day moving average is $52.95 and its 200-day moving average is $48.20. The company has a market cap of $90.247 billion and a price-to-earnings ratio of 32.77.
The company also recently declared a quarterly dividend, which is scheduled for Monday, February 3rd. Investors of record on Friday, January 3rd will be given a dividend of 0.36 per share. This represents a $1.44 dividend on an annualized basis and a yield of 2.63%. The ex-dividend date of this dividend is Tuesday, December 31st. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.35.
A number of research firms have recently commented on BMY. Analysts at Argus raised their price target on shares of Bristol-Myers Squibb from $58.00 to $62.00 in a research note to investors on Wednesday, January 15th. They now have a “buy” rating on the stock. On the ratings front, analysts at Barclays upgraded shares of Bristol-Myers Squibb from an “equal weight” rating to an “overweight” rating in a research note to investors on Friday, January 10th. They now have a $65.00 price target on the stock, up previously from $52.00. Finally, analysts at TheStreet reiterated a “buy” rating on shares of Bristol-Myers Squibb in a research note to investors on Thursday, January 9th. One analyst has rated the stock with a sell rating, six have issued a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $53.43.
Bristol-Myers Squibb Company (NYSE:BMY) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.